1. Home
  2. RVPH vs TACT Comparison

RVPH vs TACT Comparison

Compare RVPH & TACT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RVPH
  • TACT
  • Stock Information
  • Founded
  • RVPH 2006
  • TACT 1996
  • Country
  • RVPH United States
  • TACT United States
  • Employees
  • RVPH N/A
  • TACT N/A
  • Industry
  • RVPH Biotechnology: Pharmaceutical Preparations
  • TACT Computer peripheral equipment
  • Sector
  • RVPH Health Care
  • TACT Technology
  • Exchange
  • RVPH Nasdaq
  • TACT Nasdaq
  • Market Cap
  • RVPH 36.4M
  • TACT 37.5M
  • IPO Year
  • RVPH N/A
  • TACT 1996
  • Fundamental
  • Price
  • RVPH $1.20
  • TACT $3.97
  • Analyst Decision
  • RVPH Strong Buy
  • TACT Strong Buy
  • Analyst Count
  • RVPH 3
  • TACT 1
  • Target Price
  • RVPH $14.33
  • TACT $7.50
  • AVG Volume (30 Days)
  • RVPH 165.3K
  • TACT 14.0K
  • Earning Date
  • RVPH 08-12-2024
  • TACT 08-07-2024
  • Dividend Yield
  • RVPH N/A
  • TACT N/A
  • EPS Growth
  • RVPH N/A
  • TACT N/A
  • EPS
  • RVPH N/A
  • TACT 0.06
  • Revenue
  • RVPH N/A
  • TACT $61,048,000.00
  • Revenue This Year
  • RVPH N/A
  • TACT N/A
  • Revenue Next Year
  • RVPH N/A
  • TACT $21.64
  • P/E Ratio
  • RVPH N/A
  • TACT $63.67
  • Revenue Growth
  • RVPH N/A
  • TACT N/A
  • 52 Week Low
  • RVPH $1.05
  • TACT $3.32
  • 52 Week High
  • RVPH $6.80
  • TACT $9.04
  • Technical
  • Relative Strength Index (RSI)
  • RVPH 39.35
  • TACT 58.16
  • Support Level
  • RVPH $1.17
  • TACT $3.54
  • Resistance Level
  • RVPH $1.35
  • TACT $3.97
  • Average True Range (ATR)
  • RVPH 0.10
  • TACT 0.16
  • MACD
  • RVPH 0.03
  • TACT 0.04
  • Stochastic Oscillator
  • RVPH 48.33
  • TACT 100.00

About RVPH Reviva Pharmaceuticals Holdings Inc.

Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.

About TACT TransAct Technologies Incorporated

Transact Technologies Inc develops and sells software-driven technology and printing solutions. The company's software is sold under BOHA, AccuDate, Epic, EPICENTRAL, Ithaca, and Printrex brand names. It also provides supplies and consumables used in the printing and scanning activities to restaurant and hospitality, banking, retail, casino and gaming, point of sale automation, lottery, medical, mobile, oil, and gas markets. Majority of the revenue is derived from the casinos and gaming industry followed by the Foodservice technology market. Its geographical segments are the United States and International, of which the majority of its revenue comes from the United States.

Share on Social Networks: